INFLIXIMAB

Search structure
Trade Names:
Synonyms:
cA2
Status: Approved (1998)
Entry Type: Antibody
Molecule Category: UNKNOWN
ATC: L04AB02
UNII: B72HH48FLU

Pharmacology

Action Mechanism of Action Reference
INHIBITOR TNF-alpha inhibitor DailyMed

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Arthritis, Psoriatic 4 D015535 ClinicalTrials
Spondylitis, Ankylosing 4 D013167 ClinicalTrials
Arthritis, Rheumatoid 4 D001172 ClinicalTrials
Behcet Syndrome 3 D001528 ClinicalTrials
Mucocutaneous Lymph Node Syndrome 3 D009080 ClinicalTrials
Graft vs Host Disease 3 D006086 ClinicalTrials
Inflammatory Bowel Diseases 3 D015212 ClinicalTrials
Pulmonary Disease, Chronic Obstructive 3 D029424 ClinicalTrials
Arthritis, Juvenile 3 D001171 ClinicalTrials
Hepatitis C, Chronic 3 D019698 ClinicalTrials
Parapsoriasis 3 D010267 ClinicalTrials
Sarcoidosis 3 D012507 ClinicalTrials
Polymyalgia Rheumatica 3 D011111 ClinicalTrials
Anorexia 3 D000855 ClinicalTrials
Low Back Pain 3 D017116 ClinicalTrials
Cachexia 3 D002100 ClinicalTrials
Fatigue 3 D005221 ClinicalTrials
Scleritis 3 D015423 ClinicalTrials
Lung Neoplasms 3 D008175 ClinicalTrials
Graft vs Host Disease 3 D006086 ClinicalTrials
Severe Acute Respiratory Syndrome 3 D045169 ClinicalTrials
Severe Acute Respiratory Syndrome 3 D045169 ClinicalTrials
Takayasu Arteritis 2 D013625 ClinicalTrials
Stevens-Johnson Syndrome 2 D013262 ClinicalTrials
Stevens-Johnson Syndrome 2 D013262 ClinicalTrials
Granulomatosis with Polyangiitis 2 D014890 ClinicalTrials
Arthritis, Reactive 2 D016918 ClinicalTrials
Paraparesis, Tropical Spastic 2 D015493 ClinicalTrials
Wet Macular Degeneration 2 D057135 ClinicalTrials
Microscopic Polyangiitis 2 D055953 ClinicalTrials
Eosinophilic Esophagitis 2 D057765 ClinicalTrials
Spondylarthropathies 2 D025242 ClinicalTrials
Diabetes Mellitus, Type 1 2 D003922 ClinicalTrials
Reperfusion Injury 2 D015427 ClinicalTrials
Hepatitis C 2 D006526 ClinicalTrials
Colitis 2 D003092 ClinicalTrials
Bipolar Disorder 2 D001714 ClinicalTrials
Osteoarthritis 2 D010003 ClinicalTrials
Giant Cell Arteritis 2 D013700 ClinicalTrials
Pemphigus 2 D010392 ClinicalTrials
Hidradenitis Suppurativa 2 D017497 ClinicalTrials
Myelodysplastic Syndromes 2 D009190 ClinicalTrials
Dermatomyositis 2 D003882 ClinicalTrials
Endometriosis 2 D004715 ClinicalTrials
Myositis 2 D009220 ClinicalTrials
Berylliosis 1 D001607 ClinicalTrials
Granulomatous Disease, Chronic 1 D006105 ClinicalTrials

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
12.29
Injury, poisoning and procedural complications
10.78
Gastrointestinal disorders
10.31
Immune system disorders
9.14
Infections and infestations
7.68
Skin and subcutaneous tissue disorders
7.33
Respiratory, thoracic and mediastinal disorders
5.73
Musculoskeletal and connective tissue disorders
5.53
Vascular disorders
4.34
Nervous system disorders
4.26
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
3.66
Investigations
3.19
Cardiac disorders
3.13
Surgical and medical procedures
2.23

Cross References

Resources Reference
CAS NUMBER 170277-31-3
ChEMBL CHEMBL1201581
FDA SRS B72HH48FLU
Guide to Pharmacology 5004
CONTENTS